comparemela.com

Latest Breaking News On - Tony hoos - Page 1 : comparemela.com

Swedish Orphan Biovitrum : Changes to Sobi s management

Changes to Sobi s management 19 June, 2023 14:45 Tony Hoos, Head of R&D and Medical Affairs , and Chief Medical Officer , is leaving. | June 19, 2023

United statesTony hoosAnders ullmanGuido oelkersLydia abad franchSobi executive committeeMedical affairsChief medical officerClinical scienceBoard memberNorth americaMiddle eastSwedish orphan biovitrum ab publ stock exchangePress releaseS sobi se0000872095

Sobi to present new data at ISTH 2023

Sobi will present new scientific data at ISTH 2023, the 31st Congress of the International Society on Thrombosis and Haemostasis. This event, taking place from 24th to 28th June, will be held both. | June 15, 2023

United statesNew zealandSaudi arabiaCamilla sandstromTony hoosElocta eloctateHead of research developmentInternational society on thrombosisChief medicalAntihemophilic factorCanada japanMiddle easternNews publishing

EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A

/PRNewswire/ Sobi today announced that the European Medicines Agency (EMA) has accepted and validated a marketing authorisation application for.

United statesPrnewswire sobiTony hoosHead of research developmentSobi investor relations teamEuropean medicines agencyDrug administrationChief medicalNorth africaMiddle easternNorth americaMiddle eastSobi mediaOrphan biovitrumSwedish orphan biovitrum abMedical pharmaceuticals

Changes to Sobi s management

/PRNewswire/ Anton (Tony) Hoos, M.D., Ph.D., MBA will become Head of R&D and Medical Affairs and Chief Medical Officer and replace Anders Ullman, M.D., Ph.D..

United statesNorth carolinaAnton tony hoosAnders ullmanTony hoosGuido oelkersPatient focused medicine developmentSobi investor relations teamSobi executive committeeMedical affairsChief medical officerSobi executiveSobi mediaNorth americaMiddle eastOrphan biovitrum

vimarsana © 2020. All Rights Reserved.